Can any medications cause pulsatile tinnitus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Medications Cause Pulsatile Tinnitus?

Yes, medications can cause pulsatile tinnitus, though the evidence specifically linking drugs to pulsatile tinnitus (as opposed to general tinnitus) is limited. The most important clinical action is to conduct a thorough medication review in any patient presenting with pulsatile tinnitus, as drug-induced tinnitus is well-documented and potentially reversible.

Medications Known to Cause Tinnitus

While the AAO-HNS guidelines 1 focus primarily on treatment rather than etiology, they explicitly note that certain medications (particularly antidepressants) have the potential to worsen or cause tinnitus. Recent FAERS database analysis 2 identified specific high-risk medications:

Highest Risk Medications:

  • Duloxetine (ROR 11.99) - strongest association among all drugs analyzed
  • Ciprofloxacin (ROR 9.96) - second strongest association
  • Other antidepressants, anticonvulsants, and anxiolytics

The database analysis 2 revealed that among 29,460 patients with drug-related tinnitus, the most common associated drug classes were antidepressants and antibiotics (particularly fluoroquinolones).

Emerging Evidence: GLP-1 Receptor Agonists

A novel and clinically important finding is that GLP-1 receptor agonists can cause Eustachian tube dysfunction leading to tinnitus 3. The 2025 study analyzing the FDA adverse event database found:

  • 958 otologic adverse events (0.99% of all GLP-1 RA adverse events)
  • 93 cases of tinnitus specifically reported
  • Exenatide showed the highest proportion (1.52%), followed by semaglutide (1.17%) and liraglutide (1.16%)
  • Mechanism involves rapid weight loss causing loss of tissue bulk around the Eustachian tube cushions

This is particularly relevant given the explosive growth in GLP-1 RA prescribing for weight loss.

Clinical Algorithm for Medication-Related Pulsatile Tinnitus

Step 1: Medication Review

Review all current medications, focusing on:

  • Recent medication additions or dose changes (within 3-6 months)
  • Antidepressants (especially duloxetine, SSRIs)
  • Fluoroquinolone antibiotics
  • GLP-1 receptor agonists
  • Anticonvulsants and anxiolytics

Step 2: Temporal Correlation

Establish whether tinnitus onset correlates with:

  • Medication initiation
  • Dose escalation
  • Recent significant weight loss (>10% body weight)

Step 3: Trial Discontinuation

If a temporal relationship exists and the medication is not essential:

  • Consider discontinuation or substitution
  • Monitor for symptom resolution over 2-4 weeks
  • Document response

Critical Caveats

Important distinction: The guidelines 4 emphasize that pulsatile tinnitus requires different diagnostic considerations than nonpulsatile tinnitus. Pulsatile tinnitus more commonly has vascular etiologies (arterial malformations, venous abnormalities, glomus tumors) rather than medication causes. However, medications should still be reviewed as a potentially reversible contributor.

Do not assume medication causation without appropriate vascular imaging when indicated. The ACR guidelines 4 recommend targeted imaging for pulsatile tinnitus based on clinical presentation, as missing a vascular etiology could have serious consequences.

Concomitant Ototoxic Effects

When medications cause tinnitus, they frequently cause other ototoxic effects simultaneously 2:

  • Vertigo (ROR 7.51)
  • Hearing loss/hypoacusis (ROR 6.11)
  • Deafness (ROR 13.50)

The presence of these associated symptoms strengthens the likelihood of medication causation.

Treatment Considerations

While the guidelines 1 recommend against routine use of antidepressants, anticonvulsants, or anxiolytics for treating tinnitus (Grade B recommendation), this creates a clinical paradox: these same medications can cause tinnitus. This underscores the importance of medication review before considering pharmacologic treatment.

One case report 5 described successful treatment of pulsatile tinnitus with propranolol and clonazepam in a patient with arterial anatomical variation, though this represents low-quality evidence and contradicts guideline recommendations for routine benzodiazepine use.

References

Guideline

clinical practice guideline: tinnitus executive summary.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014

Research

Analysis of Drug-Related Tinnitus Based on the FDA Adverse Event Reporting System Database.

British journal of hospital medicine (London, England : 2005), 2024

Research

GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2025

Guideline

acr appropriateness criteria® tinnitus: 2023 update.

Journal of the American College of Radiology, 2023

Research

Pulsatile tinnitus: treatment with clonazepam and propranolol.

Brazilian journal of otorhinolaryngology, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.